{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T21:49:03Z","timestamp":1789076943133,"version":"build-2803163510"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2]]},"abstract":"Abstract<\/jats:title>\n \n Rationale:<\/jats:title>\n Imatinib mesylate (imatinib) is a classic tyrosine kinase inhibitor used to treat chronic myeloid leukemia. Although it is well tolerated by most patients and helps in the achievement of complete remission, a few rare imatinib-associated adverse effects such as pulmonary interstitial fibrosis have been reported. Because of its rareity, the clinical features of imatinib-induced interstitial lung disease (ILD) remain unclear.<\/jats:p>\n <\/jats:sec>\n \n Patient concerns:<\/jats:title>\n A 49-year-old Chinese man with chronic myeloid leukemia received oral treatment with imatinib and initially exhibited a good response. However, he presented with cough and fever 9 months after treatment initiation.<\/jats:p>\n <\/jats:sec>\n \n Diagnoses:<\/jats:title>\n Pulmonary computed tomography indicated diffuse interstitial fibrosis in both lungs. All tests for possible infectious pathologies provided negative results.<\/jats:p>\n <\/jats:sec>\n \n Interventions:<\/jats:title>\n The patient was diagnosed with interstitial pneumonia and treated with antibiotics; however, there was no improvement. On the basis of a suspicion of imatinib-induced ILD, imatinib was discontinued and prednisone treatment was initiated.<\/jats:p>\n <\/jats:sec>\n \n Outcomes:<\/jats:title>\n The patient's symptoms ameliorated with treatment, and imatinib was reintroduced. However, he developed cough and dyspnea again, and his treatment was switched to nilotinib as a second-line regimen. He was regularly monitored, and although his clinical symptoms ameliorated, computed tomography performed 29 months after he was diagnosed with ILD showed irreversible pulmonary interstitial fibrosis without progression.<\/jats:p>\n <\/jats:sec>\n \n Lessons:<\/jats:title>\n Clinicians should consider the possibility of severe irreversible ILD and carefully monitor patients receiving imatinib treatment.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/md.0000000000014402","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T20:42:32Z","timestamp":1551386552000},"page":"e14402","source":"Crossref","is-referenced-by-count":12,"title":["Imatinib-induced irreversible interstitial lung disease"],"prefix":"10.1097","volume":"98","author":[{"given":"Ping","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfeng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Image, Ningbo First Hospital, Ningbo, Zhejiang Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaohai","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Image, Ningbo First Hospital, Ningbo, Zhejiang Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifang","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Department of Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s12185-012-1250-3","article-title":"Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data","volume":"97","author":"Dao]","year":"2013","journal-title":"Int J Hematol"},{"issue":"(Suppl 2)","key":"R2-20230914","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1038\/sj.bjc.6602065","article-title":"Understanding the mechanisms of drug-associated interstitial lung disease","volume":"91","author":"Higenbottam","year":"2004","journal-title":"Br J Cancer"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/sj.leu.2404207","article-title":"Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate","volume":"20","author":"Ohnishi","year":"2006","journal-title":"Leukemia"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3904\/kjim.2015.30.4.550","article-title":"Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection","volume":"30","author":"Lee","year":"2015","journal-title":"Korean J Intern Med"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1445-5994.2004.00757.x","article-title":"Corticosteroid-responsive interstitial pneumonitis related to imantinib mesylate with successful rechallenge, and potential causative mechanisms","volume":"35","author":"Grimison","year":"2005","journal-title":"Intern Med J"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4046\/trd.2013.75.6.256","article-title":"Successful rechallenge with imatinib in a patient with chronic myeloid leukemia who previously experienced imatinib mesylate induced pneumonitis","volume":"75","author":"Go","year":"2013","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1148\/radiol.2283030726","article-title":"Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: preliminary experience","volume":"228","author":"Antonio","year":"2003","journal-title":"Radiology"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/10428190801896103","article-title":"Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib","volume":"49","author":"Hantschel","year":"2008","journal-title":"Leuk lymphoma"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/10428194.2011.606940","article-title":"Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib","volume":"53","author":"Delomas","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2169\/internalmedicine.46.0542","article-title":"Irreversible imatinib-induced pneumonitis following long-term imatinib administration","volume":"46","author":"Seki","year":"2007","journal-title":"Intern Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201902220-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T19:43:03Z","timestamp":1694720583000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201902220-00021"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014402","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}